by a characteristic, allergic, spreading reaction. This spreading reaction should not be confused with contact irritation, which is strictly confined to the application site and is usually associated with a burning or stinging sensation instead of a profound itch. The onset of the dermatitis (≥2 weeks after the first use of the device) indicated primary sensitisation by isobornyl acrylate, instead of a preexisting allergy to acrylates. Some patients had to discontinue use of the device as, contrary to Bolinder and colleagues' suggestions, 3 bandages and barrier sprays did not provide any relief, and the use of topical products under the adhesive was not considered a workable solution either. In contact allergy, complete avoidance of or a substantial decrease in exposure to the allergen responsible is the only effective solution, but this requires identification of the allergen, which in turn necessitates cooperation from the manufacturer. The identification of isobornyl acrylate in our case series 4 was only possible by close collaboration with several dermatology departments. Apparent difficulty in obtaining cooperation from pharmaceutical companies and no complete ingredient labels on medical devices such as FreeStyle Libre certainly contribute to incomplete investigations of many similar cases, and potentially to their underreporting. In this regard, more effort by the pharmaceutical industry to aid accurate investigations would be of great value to patients who could benefit from the advantages such devices might offer in controlling their diabetes.
We declare no competing interests. indeed reported adverse skin effects when participants were using the device, although participants with a known sensitivity to medical adhesives had been excluded from the trial. In their reply to the Correspondence of Brahimi and colleagues, Bolinder and colleagues (April 8, p 1396) 3 stated that when cutaneous side-effects did occur they were mostly managed using barriers, or topical pharmaceuticals, or both, or by relocating the device to another area of the skin. The skin symptoms were believed to be related to skin temperature, humidity, or the duration of exposure, or a combination of these factors, indicating contact irritation rather than contact allergy. However, we recently reported 4 that isobornyl acrylate, which has been shown by chemical analysis to be present in FreeStyle Libre, is a skin sensitiser, provoking allergic contact dermatitis in 12 (80%) of 15 patients. All 12 patients developed severe, itchy dermatitis on the application site, which was sometimes complicated 
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